Zai Lab Limited Unsponsored ADR (ZLAB) reported $109.98 million in revenue for the quarter ended June 2025, representing a year-over-year increase of 9.4%. EPS of -$0.37 for the same period compares to -$0.82 a year ago.
The reported revenue represents a surprise of -13.88% over the Zacks Consensus Estimate of $127.7 million. With the consensus EPS estimate being -$0.37, the company has not delivered EPS surprise.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Zai Lab Limited performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Product Revenue- ZEJULA: $41 million compared to the $49 million average estimate based on three analysts.
- Product Revenue- VYVGART: $26.5 million versus $32.4 million estimated by three analysts on average.
- Product Revenue- NUZYRA: $14.3 million versus the three-analyst average estimate of $16.27 million.
View all Key Company Metrics for Zai Lab Limited here>>>
Shares of Zai Lab Limited have returned +8.6% over the past month versus the Zacks S&P 500 composite's +1.2% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Zai Lab Limited Unsponsored ADR (ZLAB): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
